Interventions of Interest
- Dupilumab (Dupixent®, Sanofi/Regeneron)
- Omalizumab (Xolair®, Genentech/Novartis)
- Mepolizumab (Nucala®, GlaxoSmithKline)
- Reslizumab (Cinqair®, Teva)
- Benralizumab (Fasenra™, AstraZeneca)
An estimated 22 million Americans have asthma, which causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Among both young and old, asthma can have a significant impact on health and limit the ability to pursue many activities.
For questions, contact info@icer.org.
View the Key Stakeholders List.
Final Documents
Below you will find the final documents from the assessment review process:
“All five biologics modestly reduce asthma exacerbations and improve daily quality of life. However, the treatments’ net prices appear to be far out of alignment with these incremental clinical benefits, and the entire therapy class would need to see price discounts of at least 50% to reach commonly cited thresholds for cost-effectiveness.”
Public Comments
Closed